United States Chronic Inflammation Treatment Market 2025 | Granulomatous inflammation holds 58%, including foreign body granuloma and infectious granuloma

Leander, Texas and Tokyo, Japan - Nov.24.2025
As per DataM intelligence research report" The global chronic inflammation treatment market is expected to reach at a Significant CAGR during the forecast period 2024-2031." Advances in biologics and rising autoimmune conditions are shaping the chronic inflammation treatment landscape.

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/chronic-inflammation-treatment-market?Prasad

United States: Recent Industry Developments

✅ In November 2025, Pfizer launched a next-generation chronic inflammation therapy targeting autoimmune disorders with improved efficacy and reduced side effects. The innovation enhances patient outcomes and long-term disease management. This reinforces Pfizer's leadership in U.S. inflammatory disease treatments.

✅ In October 2025, AbbVie invested $40 million to expand clinical trials and manufacturing capacity for novel biologics addressing chronic inflammatory conditions such as rheumatoid arthritis. The investment accelerates patient access and production scalability. This strengthens AbbVie's role in U.S. inflammation therapeutics.

✅ In September 2025, Johnson & Johnson introduced an oral small-molecule therapy for chronic inflammation with enhanced bioavailability and tolerability for long-term use. The launch supports broader outpatient treatment adoption. This elevates J&J's presence in U.S. anti-inflammatory drug solutions.

✅ In August 2025, Bristol Myers Squibb rolled out combination therapies integrating immunomodulators and targeted anti-inflammatory agents to improve efficacy in chronic inflammatory diseases. The development enhances personalized treatment approaches. This boosts BMS's footprint in U.S. inflammation care.

Japan: Recent Industry Developments

✅ In November 2025, Takeda Pharmaceutical launched advanced treatments for chronic inflammation with dual-action biologics for autoimmune and gastrointestinal disorders. The therapies improve patient response and long-term disease control. This reinforces Takeda's leadership in Japan's inflammatory disease therapeutics.

✅ In October 2025, Daiichi Sankyo invested ¥5 billion to expand R&D and production facilities for biologics and novel small molecules targeting chronic inflammation. The investment strengthens Japan's supply chain for advanced therapies. This elevates Daiichi Sankyo's role in Japan's anti-inflammatory drug market.

✅ In September 2025, Chugai Pharmaceutical introduced combination therapies integrating cytokine inhibitors and immunomodulators for enhanced treatment of chronic inflammatory conditions. The approach improves efficacy and patient quality of life. This boosts Chugai's competitiveness in Japan's therapeutics landscape.

✅ In August 2025, Astellas Pharma Japan rolled out innovative oral and injectable therapies addressing chronic inflammation with improved safety profiles and patient adherence. The development supports Japan's growing demand for advanced anti-inflammatory solutions. This strengthens Astellas' presence in precision inflammation care.

Chronic Inflammation Treatment Market: Drivers
The chronic inflammation treatment market is experiencing significant growth due to the rising prevalence of autoimmune disorders, metabolic syndromes, and age-related inflammatory conditions worldwide. Chronic inflammation is linked to diseases such as rheumatoid arthritis, inflammatory bowel disease, and cardiovascular disorders, driving the demand for effective therapies. Advances in biologics, targeted small molecules, and anti-inflammatory drugs are improving patient outcomes and quality of life. Increasing investment in research and clinical trials is facilitating the development of novel therapeutics. Growing awareness among healthcare providers and patients about early intervention and long-term disease management is further supporting market expansion.

Emerging personalized medicine approaches and biomarker-driven treatments are enabling more precise and effective management of chronic inflammation. The integration of digital health tools, such as remote monitoring and telemedicine, is enhancing treatment adherence and patient care. Collaborations between pharmaceutical companies, biotech firms, and research institutions are accelerating the introduction of innovative therapies. Rising healthcare expenditure and insurance coverage for chronic disease management are boosting accessibility. With the global focus on preventive healthcare and improved treatment strategies, the chronic inflammation treatment market is poised for sustained growth.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/chronic-inflammation-treatment-market?Prasad

Chronic Inflammation Treatment Market: Major Players
Pfizer Inc., NodThera, Abcentra, Evommune, Inc., Sterna biologicals, Halia Therapeutics, Inc., Amgen Inc., AstraZeneca, Takeda Pharmaceutical Company Limited and Annexon, Inc. among others.

Segment Covered in the Chronic Inflammation Treatment Market:
By Type
Nonspecific proliferative inflammation leads with 42% share, driven by its prevalence in autoimmune disorders and post-injury responses. Granulomatous inflammation holds 58%, including foreign body granuloma and infectious granuloma, supported by rising cases of chronic infections and implant-related inflammation.

By Medications
Metformin captures 25% share, largely due to its anti-inflammatory effects in diabetic patients. NSAIDs hold 30%, driven by widespread use for pain and inflammation management. Statins account for 15%, supported by cardiovascular disease prevention. Corticosteroids capture 20%, used for acute and chronic inflammatory conditions. Herbal supplements hold 10%, growing with preference for natural therapies.

By Chronic Inflammation Disease Type
Diabetes dominates with 28% share, fueled by systemic inflammation and metabolic complications. Cardiovascular diseases hold 22%, supported by the link between inflammation and atherosclerosis. Arthritis and joint diseases account for 20%, COPD holds 15%, and allergies and other conditions represent 15%, driven by rising prevalence of respiratory and immune-related inflammatory disorders.

By Distribution Channel
Hospital pharmacies lead with 40% share, offering prescription medications for chronic inflammation. Retail pharmacies account for 35%, supporting OTC and long-term therapy needs. Online pharmacies hold 20%, driven by e-commerce growth, convenience, and subscription-based delivery. Other channels represent 5%, including specialty clinics and wellness stores.

Regional Analysis
North America - 32% Share
North America leads with 32%, driven by high prevalence of chronic inflammatory diseases, advanced healthcare infrastructure, and strong adoption of prescription and OTC treatments.

Europe - 25% Share
Europe holds 25%, supported by aging populations, robust healthcare systems, and rising demand for both pharmaceutical and herbal anti-inflammatory therapies.

Asia Pacific - 30% Share
Asia Pacific accounts for 30%, fueled by increasing diabetes and cardiovascular disease incidence in China, India, and Japan, alongside growing awareness and access to modern treatments.

Latin America - 7% Share
Latin America contributes 7%, driven by Brazil and Mexico, with rising chronic disease prevalence and expanding pharmacy networks.

Middle East & Africa - 6% Share
Middle East & Africa hold 6%, supported by urban healthcare infrastructure development and increasing adoption of chronic inflammation treatments in GCC countries and South Africa.

Purchase this report before year-end and unlock an exclusive 30% discount:
https://www.datamintelligence.com/buy-now-page?report=chronic-inflammation-treatment-market
(Purchase 2 or more Repots and get 50% Discount)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?Prasad

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.